ReviewThe American journal of pathology1999
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
Review in The American journal of pathology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 4 syntheses or guidelines pooled it, 412 citations in OpenAlex.
- Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus.The Cochrane database of systematic reviews · 2020Pooled it
- Meta-analysis of Barrett's esophagus in China.World journal of gastroenterology · 2013Pooled it
- A systematic review and meta-analysis of the treatment for Barrett's esophagus.Digestive diseases and sciences · 2008Pooled it
- Efficacy of Cryotherapy as a Primary Endoscopic Ablation Modality for Dysplastic Barrett's Esophagus and Early Esophageal Neoplasia: A Systematic Review and Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Immunohistochemical/histochemical double staining method in the study of the columnar metaplasia of the oesophagus.European journal of histochemistry : EJH · 2014Trial
- Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer.British journal of cancer · 2002Trial
- HPV status shapes T-cell immunoprofiles in oesophageal adenocarcinoma: high regulatory T cell infiltration predicts poor prognosis.Journal of translational medicine · 2025Article
- Potential role of immune-related LncRNAs in prognosis of hepatocellular carcinoma: an integrative study.Discover oncology · 2025Article
- Lysyl Oxidase Mediates Proliferation and Differentiation in the Esophageal Epithelium.Biomolecules · 2024Article
- Patients' values and preferences regarding endoscopic therapy for Barrett's esophagus: A cross-sectional survey study.DEN open · 2024Article
- Genetic alterations during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis.The Journal of pathology · 2022Article
- Krüppel-like Factor 5 Promotes Sonic Hedgehog Signaling and Neoplasia in Barrett's Esophagus and Esophageal Adenocarcinoma.Translational oncology · 2019Article
- Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.Digestive diseases and sciences · 2019Article
- Extracellular Matrix Degradation Products Downregulate Neoplastic Esophageal Cell Phenotype.Tissue engineering. Part A · 2019Article
- Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus.Applied immunohistochemistry & molecular morphology : AIMM · 2018Article
- Origins of Metaplasia in the Esophagus: Is This a GE Junction Stem Cell Disease?Digestive diseases and sciences · 2018Review
- Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus.Digestive diseases and sciences · 2018Review
- Germline variant in MSX1 identified in a Dutch family with clustering of Barrett's esophagus and esophageal adenocarcinoma.Familial cancer · 2018Article
- Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrin-αv trafficking.Journal of cellular and molecular medicine · 2017Article
- Modeling Esophagitis Using Human Three-Dimensional Organotypic Culture System.The American journal of pathology · 2017Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of adenocarcinoma of the esophagus has been increasing in developing countries over the last three decades and probably reflects a genuine increase in the incidence of its recognized precursor lesion, Barrett's metaplasia. Despite advances in multimodality therapy, the prognosis for invasive esophageal adenocarcinoma is poor. An improved understanding of the molecular biology of this disease may allow improved diagnosis, therapy, and prognosis. We focus on recent developments in the molecular and cell biology of Barrett's metaplasia, a heterogeneous lesion affecting the transitional zone of the gastro-esophageal junction whose associated molecular alterations may vary both in nature and temporally. Early premalignant clones produce biological and genetic heterogeneity as seen by multiple p53 mutations, p16 mutations, aneuploidy, and abnormal methylation resulting in stepwise changes in differentiation, proliferation, and apoptosis, allowing disease progression under selective pressure. Abnormalities in expression of growth factors of the epidermal growth factor family and cell adhesion molecules, especially cadherin/catenin complexes, may occur early in invasion. Exploitation of these molecular events may lead to a more appropriate diagnosis and understanding of these lesions in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.